<DOC>
	<DOCNO>NCT03091803</DOCNO>
	<brief_summary>This randomize pilot clinical trial study quantitative susceptibility mapping ( QSM ) regional dynamic contrast enhance ( DCE ) magnetic resonance imaging ( MRI ) permeability use golden-angle cartesian randomize time-resolved ( GOCART ) technique evaluate regional gadolinium retention brain patient intracranial neoplasm receive gadobenate dimeglumine gadoterate meglumine . MRI diagnostic technique , QSM DCE MRI , may help gather information regard brain change associate gadolinium deposit 8 18 month administration gadobenate dimeglumine gadoterate meglumine .</brief_summary>
	<brief_title>QSM Regional DCE MRI Permeability Using GOCART Technique</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To obtain preliminary data ( e.g . mean , variance , distribution ) regional brain parenchymal change associate gadolinium ( Gd ) deposition 8 18 month period administration gadolinium base contrast agent ( GBCA ) Gd naive intracranial neoplasm patient randomized gadobenate dimeglumine ( MultiHance ) gadoterate meglumine ( Dotarem ) . II . To explore area increase regional Gd deposition individual level correlate baseline regional DCE permeability metric volume transfer coefficient reflect vascular permeability ( kTrans ) , extracellular volume ratio reflect vascular permeability ( ) plasma volume ( vp ) intracranial neoplasm patient . OUTLINE : Patients randomize 1 2 arm . ARM I : Patients undergo standard care QSM T1 weight imaging ( T1WI ) . Patients receive gadobenate dimeglumine intravenously ( IV ) undergo GOCART DCE MRI 60 minute . ARM II : Patients undergo standard care QSM T1WI . Patients receive gadoterate meglumine IV undergo GOCART DCE MRI 60 minute . After completion study , patient follow 8-18 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N , N ' , N '' , N '' '-tetraacetate</mesh_term>
	<criteria>Patient intracranial neoplasm schedule routine MRI GBCA ( gadolinium naive patient ) Willingness comply study protocol Contraindications MRI GBCA ( standard care ) Abnormal renal function estimate glomerular filtration rate ( eGFR ) less 30 mL/min/m^2 base creatinine obtain within last 30 day History previous administration GBCA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>